INTRODUCTION
Polycystic ovarian syndrome (PCOS) remains one of the leading endocrine disorders encountered by women of reproductive age; however, the etiology and pathogenesis of this syndrome remain an area of continued debate and controversy.
PCOS is considered a syndrome due to heterogeneity in the features of this complex disorder. The Rotterdam criteria were established to confirm diagnosis of PCOS in women who have the presence of at least two of the following symptoms; hyperandrogenism, polycystic ovaries and oligo-and/or anovulation [1] . Hyperandrogenism, an increase in circulating androgen levels such as testosterone, androstenedione, or dehydroepiandrosterone, may lead to a variety of clinical features such as hirsutism, a masculine pattern of facial and body hair growth, presents as an increase in terminal hairs on the lip, chin, chest, back, abdomen, or thigh and acne, inflamed sebaceous glands of the skin [2] . Hyperandrogenemia also causes hair loss (alopecia) on the scalp as a result of sensitivity of the hair follicles to androgen [3] . Polycystic ovaries, the presence of multiple (> 10) cysts in an ovary [4] , is caused by the arrest of follicle development at an immature stage (Fig. 1) . PCOS is named in reference to this morphological change. As the development of these follicles is arrested well before the point of dominant follicle selection, and therefore positive estrogen feedback to the hypothalamus and pituitary axis is lacking, the LH surge is absent in PCOS patients [5] [6] [7] .
Consequently, ovulation and menstrual cycles are interrupted (oligovulation and oligoamenorrhea, respectively).
Endocrine features
PCOS is widely recognized as an endocrine disorder with numerous metabolic consequences. Unfortunately, the metabolic consequences of PCOS are interwoven with the metabolic consequences of obesity and causal relationships are therefore hard to define (i.e. while PCOS is classified as an endocrine disorder, obesity will affect the endocrine parameters of this disorder). Insulin resistance is one of the metabolic diseases associated with PCOS, and is perhaps the most well documented symptom [8] . The clinical manifestation of insulin resistance at a patient level reflects the complexities described above. Approximately half the women with PCOS are obese [9] and therefore prone to the presentation of insulin resistance [8] . However, insulin resistance is also observed in women with PCOS of a normal body weight [10] , together indicating that the hyperinsulinemia associated with this syndrome is not specific to the stressors associated with obesity. The relationship between glucose and insulin is also somewhat patient-specific and affected by age, race, and physical condition. Therefore, insulin resistance/glucose tolerance is a metabolic disease associated with PCOS that can manifest itself in more severe outcomes such as diabetes. Cardiovascular risk is in- The relationship between steroids, lipids and glucose metabolism is not easily defined. Interactions between these parameters are known and aberrations of one will affect the other as a metabolic consequence will modulate the endocrine environment. As such, many of the symptoms and features of PCOS play on one another to exacerbate the presentation of the others. The interconnection of the symptoms of PCOS has thus made it a large challenge to pinpoint the causal factor(s) as well as those that are secondary to that initial aberration.
Clinical treatments
PCOS is a very complex disorder with heterogeneity of clinical as well as endocrine features. To treat symptoms caused by the hyperandrogenemia of PCOS (hirsutism, acne, seborrhea and hair loss), antiandrogens such as flutamide and spironolactone are routinely administered [20] [21] [22] [23] [24] [25] [26] [27] . Most of all, however, treatment of PCOS patients has been centered on inducing ovulation. Due to an inability to naturally ovulate, PCOS patients receive either pharmacological or surgical treatments to induce ovulation together with other assisted reproductive technology (ART) procedures [28] [29] [30] [31] [32] [33] [34] . The most commonly used procedures are to increase sensitivity to insulin, induce the gonadotropin surge, or lower circulating testosterone levels. For each of the symptoms, the following treatments are used.
1) Metformin
While the etiology is unclear, it is well established that PCOS and obesity/diabetes are tightly associated. In support of this physiological relationship, weight loss not only improves insulin sensitivity but also often restores ovulatory cycles in some women with PCOS [35] [36] [37] [38] [39] [40] . This finding has led to the application of a pharmacological approach for recovering ovulatory cycles in PCOS patients using metformin, an insulin-sensitizing drug [41] [42] [43] [44] [45] . Metformin lowers blood sugar levels by decreasing the amount of sugar produced by the liver, increasing the amount of sugar absorbed by muscle cells and decreasing the body's resistance to insulin. Recent studies show that metformin is safe and effective in lowering insulin and improving fertility [46, 47] .
2) Clomiphene/gonadotropins
For a PCOS patient seeking to become pregnant, the first line of therapy may be to treat her with clomiphene citrate (CC). Clomiphene citrate is a selective estrogen receptor modulator (SERM) that acts as an estrogen receptor antagonist in the hypothalamus [48] [49] [50] [51] .
When administered, CC prevents the negative feedback effect of estrogen, thus stimulating gonadotropin releasing hormone (GnRH) from the hypothalamus, which in turn increases the secretion of gonadotropins from the pituitary. Therefore, CC is widely used to stimulate folliculogenesis and ovulation in PCOS patients. However, in some women, CC is not successful at inducing ovulation. In these cases, the direct injection gonadotropins can be used to stimulate follicle development and ovulation [52] [53] [54] .
3) Laparoscopic surgery
In women for whom CC or gonadotropin treatment is unsuccessful, another commonly used approach is ovarian surgery. Although there are several different techniques, they all involve acute ovarian tissue damage. Various types of ovarian surgery have been employed (wedge resection, electrocautery, laser vaporization, multiple ovarian biopsies and others [55] [56] [57] [58] [59] [60] . All of these procedures result in a positively altered endocrine profile after surgery. While the current hypothesis is that a small amount of damage to the ovary works to break the cycle of excessive androgen production and abnormal negative feedback, the mechanism behind the reversal of endocrinological dysfunction in PCOS after ovarian surgery remains incompletely understood.
Proposed pathogenesis
While the initiating factor of PCOS has yet to be determined, we can evaluate the collective pool of known and suspected features of PCOS to better clarify how each symptom relates and what may In regard to the mechanism of how hyperandrogenism may lead to ovulatory defect and therefore formation of follicular cyst in the ovary, it has been proposed that elevated testosterone disrupts the regulation of GnRH secretion [64] . In support of this, either GnRH agonists or LH treatment induces ovulation in PCOS patients. A few animal studies have shown that androgen suppresses progesterone receptor (PR) expression in the hypothalamus [65] [66] [67] . As progesterone down-regulates GnRH secretion by activating PR activity in the hypothalamus [68] [69] [70] , androgen-mediated suppression of PR expression may ameliorate GnRH secretion, and therefore LH secretion (Fig. 3) . This altered release of gonadotropins will lead to defects in follicle development, the development may arrest outright leading to failure to ovulate (anovulation) or be reduced leading to irregular ovulation (oligo-ovulation). The arrested follicle may thus form a cystic structure, leading to the polycystic ovarian phenotype and loss of fertility in PCOS patients.
Insulin resistance and obesity themselves are also known to negatively affect the secretion of pituitary hormones, and therefore follicular development [71] [72] [73] . It is not known whether altered steroidogenesis, pituitary hormone regulation or the defects in follicular development lead to an alteration of metabolism such as insulin 
Animal models for the study of PCOS
To identify the complex nature of this disease, suitable animal models are needed. Researchers during the past three decades have identified different animal models that mimic many of the features of PCOS in women (these are summarized in Table 1 ). These models have afforded valuable information into complex nature of PCOS.
Currently, although a genetic component to PCOS has been identified, a specific "PCOS gene" has not, and therefore a specifically targeted gene deletion for PCOS as an animal model is not available. Therefore, the majority of PCOS models that are available to date rely upon external chemical treatments with steroids, steroid precursors or steroid receptor antagonist to achieve the pathology.
Many of these models do not produce consistent results or cease to produce PCOS like symptoms once the treatment stops. Recently, Hill et al. [74] noted that their model for cardiovascular disease, the ng/mL (~50-100% elevation above normal) [76, 90] ; PCOS women, 0.5-0.7 ng/mL (~70-200% elevation above normal) [91] [92] [93] [94] and that although anovulation observed in PNA monkeys, its prevalence is also significantly less than that of PCOS women (PA monkeys: ~40%;
PCOS women ~90%) [90] .
2) Pre-pubertal androgen [80, 81] . This model is reliant on artificial hyperandrogenemia and therefore does not help identify abnormalities upstream of hyperandrogenemia.
3) Letrozole
Letrozole is an oral non-steroidal aromatase inhibitor. Inhibition of aromatase prevents the conversion of androgens to estrogens and therefore this model has similar features to the prepubertal androgen treatment [80, 82] . Immature rats (approximately 21 days old) are 
5) RU486
Mature cycling female rats are treated daily with RU486 (20 mg/ kg body weight) for more than 8 days starting on the day of estrus.
These animals exhibit increased basal LH, polycystic ovaries, ovulation blockade and metabolic defects [87] . However, this model is reversible and symptoms decrease upon cessation of the antiprogestin treatment.
6) Estradiol
The immune system is now a well-recognized component of re- sion of Cyp17, a critical enzyme that catalyzes a rate-limiting step in androgen production (Fig. 4) , resulting in the decrease of androgen production. Therefore, deleting Esr1 gene would be a logical choice for achieving sustained high levels of androgens because loss of Esr1 will exclude negative regulation of Cyp17 gene expression by estrogen. This will ultimately result in increased production of androgens.
The deletion of Esr1 gene has to be, however, limited to theca cells http://www.enm-kes.org because Esr1 is expressed in so many different tissues/organs including all of the tissues of the hypothalamic-pituitary-ovary-uterus axis [98, 99] . Otherwise, the Esr1 deletion in non-theca cells would cause other defects, making it difficult to isolate the Esr1 deletion effect in the theca cells. 
